

The Scientific Side of Medical Marijuana

Ken Mackie, MD
Indiana University
Bloomington, IN
December 3, 2009

kmackie@indiana.edu



Financial disclosures

- NIH (NIDA) - research grants
- Alzheimer's Association - research grant

- Abbott - Consulting
- Bristol Meyers Squibb - Consulting
- Cara Therapeutics - Consulting
- Sanofi - Consulting

Outline

- Introduction to cannabis and cannabinoids
- Overview of cannabinoid pharmacology relevant to medicinal uses
- Oral Δ^9 THC vs cannabis: Scientific considerations




Cannabis: A primer

- The plant: Cannabis, marijuana, etc.
 - Hemp vs psychoactive cannabis
- Major psychoactive component, $\Delta^9\text{THC}$
- However ~60 other compounds
 - Variability of constituents
- Preparations
 - Raw, dried plant (F vs. M)
 - Flowers and buds
 - Hashish
- Inhalation
 - Smoked (burned-joint, pipe, waterpipe)
 - Vaporizer (heat to release volatile compounds, $\sim 200^\circ\text{C}$)
- Ingestion
 - Cooked into foods, extract $\Delta^9\text{THC}$ into fats (butter)




Cannabis: Cannabinoid synthesis

- CBG—cannabigerol
- CBD—cannabidiol
- THC— Δ^9 tetrahydrocannabinol
- CBC—cannabichromene
- CBN—cannabinol
- "V" suffix denotes propyl instead of pentyl side chain




From GW Pharma

Cannabinoid synthesis (overview)




Endocannabinoid system (ECS)

- Desire to understand the psychoactivity of cannabis contributed to a "Golden Era" of cannabinoid research during the 1980's-1990's
- This led to the discovery of the endocannabinoid system
- Receptors, ligands, metabolic enzymes




Endocannabinoid system (ECS)

- Endocannabinoids: 2-AG, AEA
- Major degrading enzymes: FAAH, MGL
- Receptors: CB₁, CB₂, GPR55, ...




CB₁ cannabinoid receptors

- Discovered & cloned in late 1980's
- Mediates most CNS actions of Δ^9 THC
- Richly expressed in brain, particularly in regions associated with cognition, emotion, perception, movement, etc.
- Low levels in brainstem, except emetic centers
- Lethal overdose extremely rare




Stephen Eggan & David Saffen, 2004

CB₁ is expressed on axons and terminals



CB₁-green, MAP2 (dendrites) red

M. Myoga





CB₁ heavily expressed
on some axons &
terminals


CB₁ agonists inhibit neurotransmission

Typical experiment:

- Nervous tissue slice
- Patch clamp recording of synaptic inputs
- Bath apply drugs




Measure GABAergic currents in CA1




CB₁ receptor activation inhibits neurotransmission

CB₁ agonists inhibit neurotransmission in the dorsal horn of the spinal cord




Modified from Farquhar-Smith, et al 2000



Modified from Morisset & Urban, 2001


CB₂ receptors

- Multiple modes of injury increase neuronal CB₂ expression



Gl. Wotherspoon et al. / Neuroscience 135 (2005) 235–245


14 d post ligation



<http://www.jneurosci.org/cgi/content/full/29/14/4564/F1>

7 d post hemicerebellectomy

- Microglia, too




Modified from Zhang, et al 2003

CB₂ agonists as analgesics

- CB₂ agonists are devoid of measurable psychoactivity
- CB₂ agonists show strong efficacy in multiple pain models
- Need to consider actions of THC through CB₂, too

- Inflammate rat paw with carrageenan
- Treat or not with CB₂ agonist (AM1241) ± CB₁ or CB₂ antagonist
- Measure withdrawal threshold (higher threshold = more pain relief)



Nackley et al. 2003

CB₂ receptor agonists


- Neurons and microglia
- CB₂ activation decreases synaptic transmission
- Inducible—does this convey some unique therapeutic advantages?
- Preclinical studies are very promising
- Bottom line: How do they work in humans?
- Are any of the therapeutic effects of medical marijuana mediated by CB₂ receptors?

Endogenous cannabinoids

- What do endogenous cannabinoids do?
- Preformed in membrane, liberated by activation of specific lipases
- Well positioned to function as feedback regulators of neuronal function
- Produced by neurons, astrocytes, microglia
- The effects of THC will be primarily determined by its interactions with endocannabinoids



Endocannabinoid system (ECS)

- Endocannabinoids: 2-AG, AEA
- Major degrading enzymes: FAAH, MGL
- Receptors: CB₁ & CB₂



Endocannabinoids inhibit neurotransmission


- Post-synaptic neuron makes endocannabinoids that act on CB1-expressing presynaptic terminals
- Endocannabinoids are also produced by astrocytes and microglia




Bodor et al, 2005 (layer V)

Multiple forms of eCB-mediated plasticity


DSI/DSE




MSI/MSE



Slow-self inhibition (SSI)



Heterosynaptic eLTD



DSI = depolarization-induced suppression of inhibition
 MSI = metabotropic-induced suppression of inhibition

Medical Marijuana

-Cannabis as a therapeutic

- Old idea, much support for some efficacy
- Cannabis vs synthetic Δ^9 THC

-Features to consider:


- Route of administration
- Complex mix of chemicals
- "Rebel" nature of the act

-Most common indications


- Pain (multiple, including spasticity)
- Mood disorders (anxiety, depression)
- GI disturbances (including appetite stimulation)
- HIV-related symptoms

Pharmacological approaches targeting cannabinoid receptors

- Dronabinol (Δ^9 THC in sesame oil)
- Nabilone (Cesamet)
- Sativex (standardized cannabis extract)
- Medical marijuana



Δ^9 THC



Nabilone

Medical marijuana vs dronabinol


-Components

- Dronabinol, Δ^9 THC in sesame oil
- Cannabis, complex (& variable) mixture of chemicals

-Pharmacokinetics

- Oral
 - Slow
 - Variable
 - First pass metabolism
- Inhaled
 - Rapid (self-titration)
 - Minimal first pass metabolism
 - Thermal isomerization
- Effects of CBD on THC metabolism


Δ^9 THC metabolism




Grotenhermen, 2003

Inhaled vs oral route of administration

Inhaled




Oral




Grotenhermen, 2003

Variability in oral absorption between subjects (THC levels)



Grotenhermen, 2003

Time to peak effect and duration varies with route of administration



Grotenhermen, 2003

Inhaled vs oral route of administration



Inhaled

- Rapid peak THC
- Higher peak (~3 fold)
- THC > 11-OH-THC
- Similar peak THC-COOH

Oral

- Delayed peak THC
- Lower peak (~1/3)
- THC < 11-OH-THC
- Similar peak THC-COOH

Cannabidiol modifies THC effects




S. Bhattacharyya et al, 2003

- Cannabidiol (CBD) often a major component of cannabis
- CBD has no overt psychoactivity
- Multiple studies suggest CBD modulates the properties of THC
- Effects on THC metabolism
- Direct actions of CBD (e.g., blocks cue-induced reinstatement of heroin self administration)

Summary

- Cannabis—complex mixture of compounds, including THC (acting through CB_1 & CB_2 receptors), as well as other compounds (e.g., CBD)
- THC produces its effects by interacting with the endocannabinoid system
- Very real differences between oral THC and medical marijuana
 - Pharmacokinetics
 - Additional compounds present in cannabis
 - Standardization
 - Sativex

Subjective high versus plasma THC



- 15 mg THC, po
- Points are spaced 30 minutes apart
- Peak high occurs as plasma levels are declining

Grotenhermen, 2003